Global Recombinant Human Follitropin Market Growth (Status and Outlook) 2025-2031

According to this study, the global Recombinant Human Follitropin market size will reach US$ 2072 million by 2031.

Follitropin is a form of recombinant human follicle stimulating hormone used to stimulate follicle development in women with primary ovarian hypogonadism and in men with hypogonadotropic hypogonadism.

Infertility affects many people at some point in their lives, according to a new report from the World Health Organization (WHO) released in 2023. About 17.5% of adults (about one in six people worldwide) experience infertility, highlighting the urgent need to expand access to affordable, high-quality reproductive health care for those who need it. Recombinant human follitropin is used in the treatment of female infertility and male hypogonadism. The safety and effectiveness of recombinant human follitropin have been verified in a large number of clinical applications. In the future, as biosimilar technology continues to mature and costs decrease, generic drugs will gradually break the market monopoly of original drugs and improve the accessibility of treatment. Generic drug companies will further enhance their market competitiveness by optimizing production processes, improving product quality and developing long-acting preparations.

LPI (LP Information)' newest research report, the “Recombinant Human Follitropin Industry Forecast” looks at past sales and reviews total world Recombinant Human Follitropin sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Follitropin sales for 2025 through 2031. With Recombinant Human Follitropin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Follitropin industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Follitropin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Human Follitropin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Follitropin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Follitropin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Follitropin.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Follitropin market by product type, application, key players and key regions and countries.

Segmentation by Type:
75IU
150IU
300IU
Others

Segmentation by Application:
Women
Men

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
Organon
Gedeon Richter
Ferring
Changchun High-Tech
Theramex
Qilu Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more